ADReCS

Pharmaceutical Information

Drug Name	Imatinib
Drug ID	BADD_D01136
Description	Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage	For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status	approved
ATC Code	L01EA01
DrugBank ID	DB00619
KEGG ID	D08066
MeSH ID	D000068877
PubChem ID	5291
TTD Drug ID	D0AZ3C
NDC Product Code	63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII	BKJ8M8G5HI
Synonyms	Imatinib Mesylate \| Mesylate, Imatinib \| Imatinib Methanesulfonate \| Methanesulfonate, Imatinib \| STI571 \| STI-571 \| STI 571 \| Gleevec \| Glivec \| ST 1571 \| ST1571 \| CGP 57148 \| CGP57148B \| CGP-57148 \| CGP57148 \| Imatinib \| Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide

Chemical Information

Molecular Formula	C29H31N7O
CAS Registry Number	152459-95-5
SMILES	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Chronic myeloid leukaemia recurrent	16.01.07.003; 01.10.07.003	0.002071%		Not Available
Graft versus host disease in gastrointestinal tract	12.02.09.028; 10.02.01.059; 07.11.01.027	0.000112%		Not Available
Internal haemorrhage	24.07.01.072	0.000414%		Not Available
Unmasking of previously unidentified disease	08.01.03.080	0.000224%		Not Available
Infantile apnoea	22.11.02.004; 18.04.15.003	0.000112%		Not Available
Oral pigmentation	07.05.05.024	0.000112%		Not Available
Acute aortic syndrome	24.02.03.005	0.000224%		Not Available
Acute myeloid leukaemia refractory	16.01.05.008; 01.10.05.008	0.000224%		Not Available
Bone giant cell tumour benign	16.11.02.003; 15.09.01.011	0.000112%		Not Available
Cerebral venous sinus thrombosis	24.01.04.021; 17.08.03.006	0.000168%		Not Available
Congestive hepatopathy	09.01.06.027; 02.05.04.018	0.000168%		Not Available
Cutaneous T-cell lymphoma	16.17.03.002; 01.11.03.002; 23.07.04.029	0.000224%		Not Available
Dilated cardiomyopathy	02.04.01.017	0.000448%		Not Available
Erythrocyanosis	23.06.05.011; 24.03.01.008	0.000224%		Not Available
Follicular lymphoma stage III	16.28.08.003; 01.15.08.003	0.000112%		Not Available
Gastrointestinal angiectasia	07.15.04.009; 24.03.03.048	0.000280%		Not Available
Graves' disease	10.04.08.014; 06.09.04.009; 05.02.02.009	0.000112%		Not Available
Growth failure	15.03.05.015; 14.03.02.030; 05.03.02.006	0.000168%		Not Available
Haemoperitoneum	24.07.02.065; 12.01.17.007; 07.07.02.007	0.000224%		Not Available
Heavy menstrual bleeding	21.01.03.005	-	-	Not Available
Hepatic cytolysis	09.01.07.036	0.000336%		Not Available
Histiocytic sarcoma	16.21.04.004; 01.13.04.004	0.000224%		Not Available
Hyperleukocytosis	01.02.01.018	0.000224%		Not Available
Hypersensitivity pneumonitis	22.01.01.027; 10.01.03.056	0.000112%		Not Available
Illness	08.01.03.091	-	-	Not Available
Immune thrombocytopenia	10.02.01.083; 01.08.01.013	0.000336%		Not Available
Immune-mediated hepatitis	10.02.01.085; 09.01.07.037	0.000168%		Not Available
Laryngeal squamous cell carcinoma	22.08.02.012; 16.19.03.004	0.000112%		Not Available
Loss of therapeutic response	08.06.01.041	0.000604%		Not Available
Masticatory pain	15.03.04.022	0.000112%		Not Available

The 31th Page First Pre 31 32 Next Last Total 32 Pages